GRANISETRON HYDROCHLORIDE INJECTION SOLUTION

Nchi: Kanada

Lugha: Kiingereza

Chanzo: Health Canada

Viambatanisho vya kazi:

GRANISETRON (GRANISETRON HYDROCHLORIDE)

Inapatikana kutoka:

STRIDES PHARMA CANADA INC

ATC kanuni:

A04AA02

INN (Jina la Kimataifa):

GRANISETRON

Kipimo:

1MG

Dawa fomu:

SOLUTION

Tungo:

GRANISETRON (GRANISETRON HYDROCHLORIDE) 1MG

Njia ya uendeshaji:

INTRAVENOUS

Vitengo katika mfuko:

1/3/4ML

Dawa ya aina:

Prescription

Eneo la matibabu:

5-HT3 RECEPTOR ANTAGONISTS

Bidhaa muhtasari:

Active ingredient group (AIG) number: 0123183001; AHFS:

Idhini hali ya:

APPROVED

Idhini ya tarehe:

2020-08-18

Tabia za bidhaa

_Page 1 of 21 _
PRODUCT MONOGRAPH
PR
GRANISETRON HYDROCHLORIDE INJECTION
Granisetron Hydrochloride
1 mg / mL granisetron as hydrochloride, 1 mL, 3mL and 4 mL vials
Sterile Solution for Intravenous Injection
ANTIEMETIC
(5-HT
3 RECEPTOR ANTAGONIST)
STRIDES PHARMA CANADA INC.
DATE OF REVISION:
1565, Boul. Lionel-Boulet
April 5, 2023
Varennes, Quebec
Canada, J3X 1P7
CONTROL NO. 269164
_Page 2 of 21 _
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
......................................................... 3
SUMMARY PRODUCT INFORMATION
........................................................................
3
INDICATIONS AND CLINICAL USE
.............................................................................
3
CONTRAINDICATIONS
...................................................................................................
3
WARNINGS AND PRECAUTIONS
.................................................................................
3
ADVERSE REACTIONS
...................................................................................................
5
DRUG
INTERACTIONS.....................................................................................................
7
DOSAGE AND ADMINISTRATION
.................................................................................
8
OVERDOSAGE
...................................................................................................................
9
ACTION AND CLINICAL PHARMACOLOGY
............................................................... 9
STORAGE AND STABILITY
............................................................................................
11
DOSAGE FORMS, COMPOSITION AND PACKAGING
................................................ 11
PART II: SCIENTIFIC INFORMATION
..................................................................................
12
PHARMACEUTICAL INFORMATION
............................................................................
12
CLINICAL TRIALS
...........................................................